Noesis Capital Mangement Corp Grows Stock Holdings in Medtronic PLC $MDT

Noesis Capital Mangement Corp boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 123,996 shares of the medical technology company’s stock after buying an additional 6,297 shares during the quarter. Medtronic accounts for approximately 1.8% of Noesis Capital Mangement Corp’s portfolio, making the stock its 23rd largest holding. Noesis Capital Mangement Corp’s holdings in Medtronic were worth $11,809,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MDT. 1248 Management LLC purchased a new position in Medtronic in the 1st quarter valued at approximately $26,000. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the second quarter valued at $27,000. Tripletail Wealth Management LLC acquired a new stake in Medtronic in the third quarter valued at $34,000. Clean Yield Group increased its position in shares of Medtronic by 265.7% in the third quarter. Clean Yield Group now owns 384 shares of the medical technology company’s stock valued at $37,000 after buying an additional 279 shares in the last quarter. Finally, GFG Capital LLC acquired a new position in shares of Medtronic during the 2nd quarter worth $36,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on MDT shares. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Stifel Nicolaus upped their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. boosted their price target on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Finally, Truist Financial decreased their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Stock Performance

NYSE MDT opened at $99.76 on Thursday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $127.89 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 2.64 and a beta of 0.71. The business’s 50-day moving average price is $98.02 and its 200 day moving average price is $94.34. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s dividend payout ratio is currently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).